loading
前日終値:
$0.3221
開ける:
$0.3193
24時間の取引高:
5.48M
Relative Volume:
1.93
時価総額:
$38.39M
収益:
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.2053
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-12.70%
1か月 パフォーマンス:
-12.18%
6か月 パフォーマンス:
-52.12%
1年 パフォーマンス:
-84.44%
1日の値動き範囲:
Value
$0.2986
$0.32
1週間の範囲:
Value
$0.2986
$0.41
52週間の値動き範囲:
Value
$0.2589
$2.83

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
名前
Mersana Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
617-498-0020
Name
住所
840 MEMORIAL DRIVE, CAMBRIDGE
Name
職員
102
Name
Twitter
@MersanaADC
Name
次回の収益日
2025-03-03
Name
最新のSEC提出書
Name
MRSN's Discussions on Twitter

MRSN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MRSN
Mersana Therapeutics Inc
0.308 40.14M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-06 開始されました William Blair Outperform
2024-11-15 再開されました Citigroup Buy
2024-03-19 アップグレード JP Morgan Underweight → Neutral
2024-02-29 アップグレード BTIG Research Neutral → Buy
2024-02-29 アップグレード Guggenheim Neutral → Buy
2024-02-29 アップグレード Wedbush Neutral → Outperform
2023-12-04 アップグレード Citigroup Neutral → Buy
2023-07-28 ダウングレード Robert W. Baird Outperform → Neutral
2023-07-27 ダウングレード BTIG Research Buy → Neutral
2023-07-27 ダウングレード Citigroup Buy → Neutral
2023-07-27 ダウングレード Guggenheim Buy → Neutral
2023-07-27 ダウングレード JP Morgan Neutral → Underweight
2023-07-27 ダウングレード Truist Buy → Hold
2023-07-27 ダウングレード Wedbush Outperform → Neutral
2023-06-16 ダウングレード JP Morgan Overweight → Neutral
2023-06-15 開始されました Guggenheim Buy
2023-03-16 アップグレード JP Morgan Neutral → Overweight
2023-01-20 開始されました Citigroup Buy
2022-11-21 開始されました Truist Buy
2021-10-15 再開されました BTIG Research Buy
2021-08-30 開始されました H.C. Wainwright Buy
2021-03-31 開始されました Credit Suisse Neutral
2020-12-03 開始されました Stifel Buy
2020-09-29 再開されました JP Morgan Neutral
2020-04-29 開始されました BTIG Research Buy
2020-01-21 繰り返されました H.C. Wainwright Buy
2019-03-11 ダウングレード JP Morgan Neutral → Underweight
2018-11-14 アップグレード Leerink Partners Mkt Perform → Outperform
2018-05-08 開始されました Robert W. Baird Outperform
2018-03-19 ダウングレード JP Morgan Overweight → Neutral
すべてを表示

Mersana Therapeutics Inc (MRSN) 最新ニュース

pulisher
Jul 25, 2025

MRSN Trading Halted Due to Pending News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Will Mersana Therapeutics Inc. stock split in the near futureFree Investment Case Studies - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Announces Reverse Stock Split - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com Australia

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

Jul 23, 2025
pulisher
Jul 23, 2025

12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Group Entry - Newser

Jul 22, 2025
pulisher
Jul 18, 2025

Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Mersana Therapeutics Inc. stock price move sharplyTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Mersana Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Wealth Enhancement Advisory Services LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jul 11, 2025
pulisher
Jul 05, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Mersana Therapeutics Settles Debt with Oxford Finance - TipRanks

Jul 03, 2025

Mersana Therapeutics Inc (MRSN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Mersana Therapeutics Inc (MRSN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Mandelia Ashish
VP, Chief Accounting Officer
Jan 16 '25
Sale
0.58
3,554
2,061
57,519
Protopapas Anna
Director
Jan 15 '25
Option Exercise
0.00
21,250
0
176,678
Protopapas Anna
Director
Jan 16 '25
Sale
0.58
8,637
5,009
168,041
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 15 '25
Option Exercise
0.00
19,791
0
265,721
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 16 '25
Sale
0.58
8,048
4,668
257,673
Huber Martin H. Jr.
President, CEO
Jan 15 '25
Option Exercise
0.00
11,062
0
127,389
Huber Martin H. Jr.
President, CEO
Jan 16 '25
Sale
0.58
4,514
2,618
122,875
DeSchuytner Brian
SVP, COO & CFO
Jan 15 '25
Option Exercise
0.00
20,833
0
129,863
DeSchuytner Brian
SVP, COO & CFO
Jan 16 '25
Sale
0.58
8,470
4,913
121,393
Carvajal Alejandra
SVP, Chief Legal Officer
Jan 15 '25
Option Exercise
0.00
12,500
0
83,392
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):